Journal of obstetrics and gynaecology Canada最新文献

英文中文

Letter to the Editor: Exploring Barriers and Facilitators to COVID-19 Vaccination in People Planning Pregnancy, Trying to Conceive, Pregnant and Postpartum 致编辑的信：探讨计划怀孕、尝试怀孕、怀孕和产后人群接种 COVID-19 疫苗的障碍和促进因素

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-09-01 DOI: 10.1016/j.jogc.2024.102620

Hinpetch Daungsupawong PhD , Viroj Wiwanitkit MD

引用次数: 0

Pre-delivery BMI and the Accuracy of Fetal Weight Estimation in Very Preterm Infants 极早产儿分娩前体重指数和胎儿体重估计的准确性。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-28 DOI: 10.1016/j.jogc.2024.102643

Inshirah Sgayer MD , Saaed Awwad MD , Ala Aiob MD , Susana Mustafa Mikhail MD , Lior Lowenstein MD , Marwan Odeh MD

Objectives

To examine the relation between maternal pre-delivery BMI and the accuracy of sonographic estimated fetal weight (EFW) in very preterm infants (<32 weeks gestation).

Methods

This retrospective study included singleton infants born between January 2010 and March 2023, at gestational ages 23⁰ to 31⁶ weeks, at a tertiary university-affiliated hospital. Absolute weight, percentage error, absolute percentage error, and overestimation and underestimation of EFW were compared between women with pre-delivery normal weight (BMI 18.5–24.99 kg/m²), overweight (BMI 25.0–29.99 kg/m²), and obesity (BMI >35.0 kg/m²). Multivariate linear regression analyses adjusted for potential confounders were performed to assess relations of maternal pre-conception and of pre-delivery BMI, with EFW accuracy.

Results

Included were 286 pregnancies. The absolute difference, percentage error, absolute percentage error, error within the 10% range, and underestimation or overestimation of EFW were similar between the groups. The multivariate linear regression analyses did not show significant associations of pre-conceptional BMI or of pre-delivery BMI with the percentage error. However, for small for gestational age compared to appropriate for gestational age fetuses, the percentage error was greater (8.9% vs. –0.6%, β = 0.35, P < 0.001) and the absolute percentage error was greater (11.0% vs. 6.7%, P < 0.001). Small for gestational age fetuses were at risk of fetal weight overestimation (percentage error exceeding 15%); OR 7.20 (95% CI 2.91–17.80).

Conclusions

Maternal pre-delivery BMI was not found to be related to EFW accuracy in very preterm infants. Nevertheless, EFW should be interpreted carefully, as it may underdiagnose poor fetal growth in this population.

研究目的研究极早产儿中产妇分娩前体重指数（BMI）与超声估算胎儿体重（EFW）准确性之间的关系（方法：这项回顾性研究纳入了 2010 年 1 月至 2023 年 3 月期间在一所大学附属三级医院出生的孕龄为 23+0 至 31+6 周的单胎婴儿。比较了分娩前体重正常（BMI 18.5-24.99 kg/m2）、超重（BMI 25.0-29.99 kg/m2）和肥胖（BMI >35.0 kg/m2）产妇的绝对体重、百分比误差、绝对百分比误差以及高估和低估EFW。对潜在的混杂因素进行了多变量线性回归分析，以评估孕产妇孕前和分娩前体重指数与 EFW 准确性的关系：结果：共纳入 286 例妊娠。各组间的绝对差异、百分比误差、绝对百分比误差、10%范围内的误差以及EFW的低估或高估情况相似。多变量线性回归分析表明，受孕前体重指数或分娩前体重指数与百分比误差无明显关联。然而，小胎龄胎儿与适龄胎儿相比，百分比误差更大（8.9% 对 -0.6%，β = 0.35，P < 0.001），绝对百分比误差更大（11.0% 对 6.7%，P < 0.001）。胎龄小的胎儿有胎儿体重被高估的风险（百分比误差超过 15%）；几率比 7.20 (95% CI 2.91-17.80)：结论：在极早产儿中，母体分娩前体重指数与胎儿体重测量的准确性无关。尽管如此，EFW仍需谨慎解释，因为它可能会对该人群中胎儿发育不良的情况诊断不足。

{"title":"Pre-delivery BMI and the Accuracy of Fetal Weight Estimation in Very Preterm Infants","authors":"Inshirah Sgayer MD , Saaed Awwad MD , Ala Aiob MD , Susana Mustafa Mikhail MD , Lior Lowenstein MD , Marwan Odeh MD","doi":"10.1016/j.jogc.2024.102643","DOIUrl":"10.1016/j.jogc.2024.102643","url":null,"abstract":"<div><h3>Objectives</h3><p>To examine the relation between maternal pre-delivery BMI and the accuracy of sonographic estimated fetal weight (EFW) in very preterm infants (<32 weeks gestation).</p></div><div><h3>Methods</h3><p>This retrospective study included singleton infants born between January 2010 and March 2023, at gestational ages 23<sup>0</sup> to 31<sup>6</sup> weeks, at a tertiary university-affiliated hospital. Absolute weight, percentage error, absolute percentage error, and overestimation and underestimation of EFW were compared between women with pre-delivery normal weight (BMI 18.5–24.99 kg/m<sup>2</sup>), overweight (BMI 25.0–29.99 kg/m<sup>2</sup>), and obesity (BMI >35.0 kg/m<sup>2</sup>). Multivariate linear regression analyses adjusted for potential confounders were performed to assess relations of maternal pre-conception and of pre-delivery BMI, with EFW accuracy.</p></div><div><h3>Results</h3><p>Included were 286 pregnancies. The absolute difference, percentage error, absolute percentage error, error within the 10% range, and underestimation or overestimation of EFW were similar between the groups. The multivariate linear regression analyses did not show significant associations of pre-conceptional BMI or of pre-delivery BMI with the percentage error. However, for small for gestational age compared to appropriate for gestational age fetuses, the percentage error was greater (8.9% vs. –0.6%, β = 0.35, <em>P <</em> 0.001) and the absolute percentage error was greater (11.0% vs. 6.7%, <em>P <</em> 0.001). Small for gestational age fetuses were at risk of fetal weight overestimation (percentage error exceeding 15%); OR 7.20 (95% CI 2.91–17.80).</p></div><div><h3>Conclusions</h3><p>Maternal pre-delivery BMI was not found to be related to EFW accuracy in very preterm infants. Nevertheless, EFW should be interpreted carefully, as it may underdiagnose poor fetal growth in this population.</p></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Clinical Outcomes in the Slow-Developing Blastocysts With or Without Preimplantation Genetic Testing-Aneuploidy on Day 6 in the Frozen–Thawed Cycle 冷冻解冻周期第 6 天植入前遗传学检测-非整倍体与未植入前遗传学检测-发育缓慢的囊胚临床结果的比较。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-22 DOI: 10.1016/j.jogc.2024.102644

Hee Jun Lee MD, PhD , Jae Eun Park MD , Jihye Jeong MS , Tae Hyung Kim BS , Sola Yoon MS , Jisoo Han PhD , Jin Hee Eum PhD , Hyelim Sung MD , Youngsok Choi PhD , Woo Sik Lee MD, PhD

Objectives

This study investigated the potential of the slow-developing blastocysts using preimplantation genetic testing-aneuploidy (PGT-A) in patients undergoing frozen–thawed embryo transfer, stratified by age.

Methods

A retrospective analysis was performed including a total of 743 cycles, the first frozen embryo transfer (FET) cycle with single embryo transfer, who underwent treatment between January 2020 and July 2023 in a single fertility centre, Gangnam CHA Fertility Center. A total of 743 cycles, in which we performed intracellular sperm injection and freeze-all strategy, from 743 patients were included. The patient group was divided into 4 groups as follows: group 1 (G1), 208 FET on day 5; group 2 (G2), 177 FET with PGT-A on day 5; group 3 (G3), 220 FET on day 6; group 4 (G4), 138 FET with PGT-A on day 6. We also divided into 2 groups—under 35 years of age and over 35 years of age—and performed the analysis separately for each group.

Results

In the under 35 years of age group, there were no significant differences in clinical pregnancy and miscarriage rates in G1 and G2 (67.2% vs. 63.8%, not statistically significantly different). Also, G4 had a higher clinical pregnancy rate than G3, but it was not significant (51.8% vs. 54.7%, not statistically significantly different). In the 35 years or older group, G2 had higher pregnancy rates than G1 and lower miscarriage rates (clinical pregnancy rate: 43.3% vs. 67.7%, P = 0.001, miscarriage rate: 22.5% vs. 3.4%, P = 0.001). In addition, G4 had a higher pregnancy rate than G3 and a lower miscarriage rate (clinical pregnancy rate: 31.8% vs. 46.9%, P = 0.003, miscarriage rate: 22.9% vs. 2.2%, P = 0.023).

Conclusions

In the under-35-year-old group, PGT-A on day 5 and day 6 showed a high pregnancy rate and a low miscarriage rate. Therefore, using PGT-A seems advantageous for patients of an advanced maternal age.

研究目的本研究采用植入前遗传学检测-非整倍体（PGT-A）对接受冻融胚胎移植的患者中发育缓慢的囊胚的潜力进行了调查，并按年龄进行了分层：研究进行了一项回顾性分析，共纳入了 743 例在 2020 年 1 月至 2023 年 7 月期间在 XXXX 生育中心接受治疗的首次冷冻胚胎移植（FET）周期的单胚胎移植（SET）患者。我们共纳入了 743 例患者的 743 个周期，在这些周期中，我们进行了细胞内精子注射并冻结了所有策略。患者分为以下 4 组：第 1 组（G1），第 5 天进行 208 次 FET；第 2 组（G2），第 5 天进行 177 次 FET 并使用 PGT-A；第 3 组（G3），第 6 天进行 220 次 FET；第 4 组（G4），第 6 天进行 138 次 FET 并使用 PGT-A。我们还将患者分为两组--35 岁以下组和 35 岁以上组，并对每组分别进行了分析：在 35 岁以下组中，G1 和 G2 的临床妊娠率和流产率无明显差异（67.2% vs 63.8%，NS）。此外，G4 的临床妊娠率高于 G3，但差异不显著（51.8% vs 54.7%，NS）。在 35 岁或以上组中，G2 的妊娠率高于 G1，流产率较低（CPR：43.3% vs 67.7%，P = 0.001；MR：22.5% vs 3.4%，P = 0.001）。此外，G4 的妊娠率高于 G3，流产率较低（CPR：31.8% vs. 46.9%，P = 0.003；MR：22.9% vs. 2.2%，P = 0.023）：在年龄≥35 岁组中，第 5 天和第 6 天的 PGT-A 显示了较高的妊娠率和较低的流产率。因此，使用 PGT-A 似乎对高龄产妇有利。

{"title":"Comparison of Clinical Outcomes in the Slow-Developing Blastocysts With or Without Preimplantation Genetic Testing-Aneuploidy on Day 6 in the Frozen–Thawed Cycle","authors":"Hee Jun Lee MD, PhD , Jae Eun Park MD , Jihye Jeong MS , Tae Hyung Kim BS , Sola Yoon MS , Jisoo Han PhD , Jin Hee Eum PhD , Hyelim Sung MD , Youngsok Choi PhD , Woo Sik Lee MD, PhD","doi":"10.1016/j.jogc.2024.102644","DOIUrl":"10.1016/j.jogc.2024.102644","url":null,"abstract":"<div><h3>Objectives</h3><p>This study investigated the potential of the slow-developing blastocysts using preimplantation genetic testing-aneuploidy (PGT-A) in patients undergoing frozen–thawed embryo transfer, stratified by age.</p></div><div><h3>Methods</h3><p>A retrospective analysis was performed including a total of 743 cycles, the first frozen embryo transfer (FET) cycle with single embryo transfer, who underwent treatment between January 2020 and July 2023 in a single fertility centre, Gangnam CHA Fertility Center. A total of 743 cycles, in which we performed intracellular sperm injection and freeze-all strategy, from 743 patients were included. The patient group was divided into 4 groups as follows: group 1 (G1), 208 FET on day 5; group 2 (G2), 177 FET with PGT-A on day 5; group 3 (G3), 220 FET on day 6; group 4 (G4), 138 FET with PGT-A on day 6. We also divided into 2 groups—under 35 years of age and over 35 years of age—and performed the analysis separately for each group.</p></div><div><h3>Results</h3><p>In the under 35 years of age group, there were no significant differences in clinical pregnancy and miscarriage rates in G1 and G2 (67.2% vs. 63.8%, not statistically significantly different). Also, G4 had a higher clinical pregnancy rate than G3, but it was not significant (51.8% vs. 54.7%, not statistically significantly different). In the 35 years or older group, G2 had higher pregnancy rates than G1 and lower miscarriage rates (clinical pregnancy rate: 43.3% vs. 67.7%, <em>P</em> = 0.001, miscarriage rate: 22.5% vs. 3.4%, <em>P</em> = 0.001). In addition, G4 had a higher pregnancy rate than G3 and a lower miscarriage rate (clinical pregnancy rate: 31.8% vs. 46.9%, <em>P</em> = 0.003, miscarriage rate: 22.9% vs. 2.2%, <em>P</em> = 0.023).</p></div><div><h3>Conclusions</h3><p>In the under-35-year-old group, PGT-A on day 5 and day 6 showed a high pregnancy rate and a low miscarriage rate. Therefore, using PGT-A seems advantageous for patients of an advanced maternal age.</p></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Length of Postpartum Hospital Stays During COVID-19: Findings From a Convergent Parallel Mixed-Methods Study COVID-19 期间产后住院时间：会聚平行混合方法研究的结果。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-21 DOI: 10.1016/j.jogc.2024.102637

Rebecca H. Correia PhD , Devon Greyson PhD , Andrea Carruthers MHK , Cassandra Kuyvenhoven PhD , David Kirkwood MSc , Aaron Jones PhD , Michelle Howard PhD , Elizabeth Darling RM, PhD , Amie Davis MD , Sarah D. McDonald MSc, MD , Caroline Mniszak MLIS , Sujane Kandasamy PhD , Meredith Vanstone PhD

Objectives

We examined the length of postpartum hospitalization for live births during the COVID-19 pandemic and explored how pandemic circumstances influenced postpartum hospital experiences.

Methods

We conducted a cross-provincial, convergent parallel mixed-methods study in Ontario (ON) and British Columbia (BC), Canada. We included birthing persons (BPs) with an in-hospital birth in ON from 1 January to 31 March 2019, 2021, and 2022 (quantitative), and BPs (≥18 years) in ON or BC from 1 May 2020 to 1 December 2021 (qualitative). We linked multiple health administrative datasets at ICES and developed multivariable linear regression models to examine the length of hospital stay (quantitative). We conducted semi-structured interviews using qualitative descriptive to understand experiences of postpartum hospitalization (qualitative). Data integration occurred during design and interpretation.

Results

Relative to 2019, postpartum hospital stays decreased significantly by 3.29 hours (95% CI –3.58 to –2.99; 9.2% reduction) in 2021 and 3.89 hours (95% CI –4.17 to –3.60; 9.0% reduction) in 2022. After adjustment, factors associated with shortened stays included: giving birth during COVID-19, social deprivation (more ethnocultural diversity), midwifery care, multiparity, and lower newborn birth weight. Postpartum hospital experiences were impacted by risk perception of COVID-19 infection, clinical care and hospital services/amenities, visitor policies, and duration of stay.

Conclusions

Length of postpartum hospital stays decreased during COVID-19, and qualitative findings described unmet needs for postpartum services. The integration of large administrative and interview data expanded our understanding of observed differences. Future research should investigate the impacts of shortened stays on health service outcomes and personal experiences.

目的：我们研究了 COVID-19 大流行期间活产婴儿的产后住院时间，并探讨了大流行环境如何影响产后住院经历。方法：我们在加拿大安大略省（ON）和不列颠哥伦比亚省（BC）开展了一项跨省、趋同平行混合方法研究。我们纳入了 2019 年 1 月 1 日至 2021 年 3 月 31 日、2021 年和 2022 年 1 月 1 日至 3 月 31 日在安大略省（定量）住院分娩的分娩者（BPs），以及 2020 年 5 月 1 日至 2021 年 12 月 1 日在安大略省或不列颠哥伦比亚省（定性）住院分娩的分娩者（≥18 岁）。我们连接了 ICES 的多个卫生行政数据集，并开发了多变量线性回归模型来检查住院时间（定量）。我们采用定性描述法进行了半结构化访谈，以了解产后住院的经历（定性）。结果：与 2019 年相比，2021 年的产后住院时间显著减少了 3.29 小时（95% CI：-3.58 到 -2.99；减少 9.2%），2022 年减少了 3.89 小时（95% CI：-4.17 到 -3.60；减少 9.0%）。经过调整后，与缩短住院时间相关的因素包括：在 COVID-19 期间分娩、社会贫困（更多种族文化多样性）、助产护理、多胎妊娠以及新生儿出生体重较轻。产后住院经历受到 COVID-19 感染风险认知、临床护理和医院服务/设施、访客政策以及住院时间的影响。结论：COVID-19 期间产后住院时间缩短，定性研究结果表明产后服务需求未得到满足。大量行政数据和访谈数据的整合扩大了我们对观察到的差异的理解。目的：我们研究了 COVID-19 大流行期间活产病例的产后住院时间，并探讨了大流行的环境对产后住院经历的影响。方法：我们在加拿大安大略省（ON）和不列颠哥伦比亚省（BC）进行了一项跨省研究，采用了混合平行和趋同设计。我们纳入了 2019 年、2021 年和 2022 年 1 月 1 日至 3 月 31 日期间在安大略省医院分娩的人（定量），以及 2020 年 5 月 1 日至 2021 年 12 月 1 日期间在安大略省或不列颠哥伦比亚省分娩的人（≥ 18 岁）（定性）。我们将多个行政健康数据集与 ICES 相连接，并开发了多变量线性回归模型来检查住院时间（定量）。我们采用描述性定性方法进行了半结构化访谈，以了解产后住院经历（定性）。在研究设计和解释过程中进行了数据整合。结果：与2019年相比，2021年产后住院时间显著减少了3.29小时（95% CI：-3.58至-2.99；减少9.2%），2022年减少了3.89小时（95% CI：-4.17至-3.60；减少9.0%）。经调整后，与缩短住院时间相关的因素有：在 COVID-19 大流行期间分娩、缺乏社会化（民族文化更加多样化）、助产护理、多胎妊娠和新生儿出生体重较轻。产后住院经历受感染 COVID-19 的感知风险、临床护理和医院服务及设施、访客政策以及住院时间的影响。整合大型行政数据集和访谈数据集有助于深入了解观察到的差异。未来的研究应探讨缩短住院时间对医疗服务成果和个人经历的影响。

{"title":"Length of Postpartum Hospital Stays During COVID-19: Findings From a Convergent Parallel Mixed-Methods Study","authors":"Rebecca H. Correia PhD , Devon Greyson PhD , Andrea Carruthers MHK , Cassandra Kuyvenhoven PhD , David Kirkwood MSc , Aaron Jones PhD , Michelle Howard PhD , Elizabeth Darling RM, PhD , Amie Davis MD , Sarah D. McDonald MSc, MD , Caroline Mniszak MLIS , Sujane Kandasamy PhD , Meredith Vanstone PhD","doi":"10.1016/j.jogc.2024.102637","DOIUrl":"10.1016/j.jogc.2024.102637","url":null,"abstract":"<div><h3>Objectives</h3><p>We examined the length of postpartum hospitalization for live births during the COVID-19 pandemic and explored how pandemic circumstances influenced postpartum hospital experiences.</p></div><div><h3>Methods</h3><p>We conducted a cross-provincial, convergent parallel mixed-methods study in Ontario (ON) and British Columbia (BC), Canada. We included birthing persons (BPs) with an in-hospital birth in ON from 1 January to 31 March 2019, 2021, and 2022 (quantitative), and BPs (≥18 years) in ON or BC from 1 May 2020 to 1 December 2021 (qualitative). We linked multiple health administrative datasets at ICES and developed multivariable linear regression models to examine the length of hospital stay (quantitative). We conducted semi-structured interviews using qualitative descriptive to understand experiences of postpartum hospitalization (qualitative). Data integration occurred during design and interpretation.</p></div><div><h3>Results</h3><p>Relative to 2019, postpartum hospital stays decreased significantly by 3.29 hours (95% CI –3.58 to –2.99; 9.2% reduction) in 2021 and 3.89 hours (95% CI –4.17 to –3.60; 9.0% reduction) in 2022. After adjustment, factors associated with shortened stays included: giving birth during COVID-19, social deprivation (more ethnocultural diversity), midwifery care, multiparity, and lower newborn birth weight. Postpartum hospital experiences were impacted by risk perception of COVID-19 infection, clinical care and hospital services/amenities, visitor policies, and duration of stay.</p></div><div><h3>Conclusions</h3><p>Length of postpartum hospital stays decreased during COVID-19, and qualitative findings described unmet needs for postpartum services. The integration of large administrative and interview data expanded our understanding of observed differences. Future research should investigate the impacts of shortened stays on health service outcomes and personal experiences.</p></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy Outcomes in Survivors of Adolescent and Young Adult Breast Cancer: A Population-Based Cohort Study 青少年和年轻成人乳腺癌幸存者的妊娠结局：一项基于人群的队列研究。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-21 DOI: 10.1016/j.jogc.2024.102638

Aisha Nathoo MSc , Susan B. Brogly PhD , Maria P. Velez MD, PhD

Objectives

To evaluate the association between adolescent and young adult (AYA) breast cancer (BC) and the adverse pregnancy outcomes of preterm birth, small for gestational age birth, cesarean delivery, and preeclampsia, and the effect of fertility treatment on this association.

Methods

Population-based cohort study with universal coverage health data for Ontario, Canada. BC was identified from the Ontario Cancer Registry. All births >22⁰ weeks gestation between April 2006 to March 2018 were included. Modified Poisson regression generated risk ratios between AYA BC and adverse pregnancy outcomes, adjusted for maternal characteristics. Models were stratified by fertility treatment.

Results

Among 1 189 980 deliveries, 474 mothers had AYA BC history (exposed), while 1 189 506 had no cancer history (unexposed). AYA BC was associated with cesarean delivery (adjusted risk ratio [aRR] 1.26; 95% CI 1.14–1.39). There was no association between AYA BC and other adverse outcomes. Modelling cesarean delivery subtypes, AYA BC was associated with increased risk of planned (aRR 1.27; 95% CI 1.08–1.49) and unplanned cesarean delivery (aRR 1.41; 95% CI 1.20–1.66). An increased risk of cesarean delivery in exposed persisted among singleton pregnancies (aRR 1.27; 95% CI 1.15–1.41), but not in models stratified by mode of conception (fertility treatment: aRR 1.07; 95% CI 0.84–1.36; unassisted conception: aRR 1.30; 95% CI 1.16–1.46).

Conclusions

A history of AYA BC did not confer an elevated risk of adverse pregnancy outcomes, except for planned and unplanned cesarean delivery. The risk of adverse pregnancy outcomes does not appear to be an indication for delayed pregnancy after AYA BC diagnosis.

研究目的评估青少年乳腺癌（AYA）与早产、小于胎龄产、剖宫产和子痫前期等不良妊娠结局之间的关联，以及生育治疗对这种关联的影响：方法：基于加拿大安大略省全民健康数据的人群队列研究。先兆子痫是从安大略省癌症登记处确定的。研究纳入了 2006 年 4 月至 2018 年 3 月期间妊娠期大于 22 周的所有新生儿。修改后的泊松回归生成了AYA BC与不良妊娠结局之间的风险比，并对产妇特征进行了调整。模型按生育治疗分层：在 1 189 980 例分娩中，474 位母亲有 AYA BC 病史（暴露），1 189 506 位母亲无癌症病史（未暴露）。AYA BC 与剖宫产有关（aRR 1.26，95% CI 1.14-1.39）。AYA BC 与其他不良后果之间没有关联。在建立剖宫产亚型模型时，AYA BC 与计划内剖宫产（aRR 1.27，95% CI 1.08-1.49）和计划外剖宫产（aRR 1.41，95% CI 1.20-1.66）风险增加有关。在单胎妊娠中，暴露的剖宫产风险持续增加（aRR 1.27，95% CI 1.15-1.41），但在按受孕方式分层的模型中（生育治疗：aRR 1.07，95% CI 0.84-1.36；非辅助受孕：aRR 1.30，95% CI 1.16-1.46），暴露的剖宫产风险没有增加：除了计划内和计划外剖宫产外，AYA BC 史并不会增加不良妊娠结局的风险。不良妊娠结局的风险似乎并不是诊断出 AYA BC 后推迟妊娠的指征。

{"title":"Pregnancy Outcomes in Survivors of Adolescent and Young Adult Breast Cancer: A Population-Based Cohort Study","authors":"Aisha Nathoo MSc , Susan B. Brogly PhD , Maria P. Velez MD, PhD","doi":"10.1016/j.jogc.2024.102638","DOIUrl":"10.1016/j.jogc.2024.102638","url":null,"abstract":"<div><h3>Objectives</h3><p>To evaluate the association between adolescent and young adult (AYA) breast cancer (BC) and the adverse pregnancy outcomes of preterm birth, small for gestational age birth, cesarean delivery, and preeclampsia, and the effect of fertility treatment on this association.</p></div><div><h3>Methods</h3><p>Population-based cohort study with universal coverage health data for Ontario, Canada. BC was identified from the Ontario Cancer Registry. All births >22<sup>0</sup> weeks gestation between April 2006 to March 2018 were included. Modified Poisson regression generated risk ratios between AYA BC and adverse pregnancy outcomes, adjusted for maternal characteristics. Models were stratified by fertility treatment.</p></div><div><h3>Results</h3><p>Among 1 189 980 deliveries<strong>,</strong> 474 mothers had AYA BC history (exposed), while 1 189 506 had no cancer history (unexposed). AYA BC was associated with cesarean delivery (adjusted risk ratio [aRR] 1.26; 95% CI 1.14–1.39). There was no association between AYA BC and other adverse outcomes. Modelling cesarean delivery subtypes, AYA BC was associated with increased risk of planned (aRR 1.27; 95% CI 1.08–1.49) and unplanned cesarean delivery (aRR 1.41; 95% CI 1.20–1.66). An increased risk of cesarean delivery in exposed persisted among singleton pregnancies (aRR 1.27; 95% CI 1.15–1.41), but not in models stratified by mode of conception (fertility treatment: aRR 1.07; 95% CI 0.84–1.36; unassisted conception: aRR 1.30; 95% CI 1.16–1.46).</p></div><div><h3>Conclusions</h3><p>A history of AYA BC did not confer an elevated risk of adverse pregnancy outcomes, except for planned and unplanned cesarean delivery. The risk of adverse pregnancy outcomes does not appear to be an indication for delayed pregnancy after AYA BC diagnosis.</p></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1701216324004614/pdfft?md5=41e88a6947b81fb7a1d43cc1bd3e3f5e&pid=1-s2.0-S1701216324004614-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Association of Polycystic Ovarian Syndrome and Adnexal Pathologies in Adolescents 青少年多囊卵巢综合征与附件病变的关联。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-13 DOI: 10.1016/j.jogc.2024.102634

Anna Y. Lynn PhD , Christina Lepore MD , Nadia Solomon MD, MSc , Mark Zamani MS , Anne Sailer MD , Alexander M. Kuehne MD , Erin Rowe MD , Alla Vash-Margita MD

引用次数: 0

Mesenteric Ischemia in a Patient on Levonorgestrel Containing Oral Contraception 一名服用含左炔诺孕酮口服避孕药的患者出现肠系膜缺血。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-10 DOI: 10.1016/j.jogc.2024.102633

Christopher Weeraj MBBS , Ballan Kannan FRCS

引用次数: 0

The Association of Vitamin D with Uterine Fibroids in Premenopausal Patients: A Systematic Review and Meta-Analysis 维生素 D 与绝经前患者子宫肌瘤的关系：系统回顾与元分析》（The Association of Vitamin D with Uterine Fibroids in Premenopausal Patients: a Systematic Review and Meta-Analysis）。

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-10 DOI: 10.1016/j.jogc.2024.102632

Marina Ivanova BHSc, BScN , Allison Soule BSc , Jessica Pudwell MSc, MPH , Olga Bougie MD, MPH

Objective

This study aims to consolidate existing literature regarding the association between vitamin D and uterine fibroid presence and growth.

Data sources

A comprehensive search across databases including Medline, Embase, CINAHL, Web of Science, ClinicalTrials.gov, and grey literature was conducted from inception to February 2023, using relevant keywords. Authors were contacted for unpublished data.

Study selection

From 9931 studies screened based on title and abstract, those evaluating serum vitamin D levels or vitamin D treatment effects, using ultrasonography for diagnosis, and involving at least 25 premenopausal participants were included. Case reports, case series, and reviews were excluded.

Data extraction and synthesis

Data were extracted using a predefined form. Methodological quality was assessed through the Newcastle-Ottawa Scale and the Risk of Bias-2 tools. Evidence quality was evaluated using Grading of Recommendations Assessment, Development, and Evaluation. Data from 3 randomised controlled trials (n = 328) and 23 observational studies (n = 5650) were meta-analyzed via random-effects modelling. Patients receiving oral vitamin D supplementation had a significantly different change in fibroid size (standardized mean difference −5.7%; CI −10.63 to −0.76, P = 0.02, I² = 99%), as measured by the percentage change in diameter or volume, compared to controls, over the span of 2–6 months. Those receiving supplementation had vitamin D insufficiency; regimens varied between 50 000 IU weekly for 12 weeks, 50 000 IU weekly for 8 weeks, and 50 000 IU biweekly for 10 weeks. Patients with fibroids exhibited lower serum vitamin D concentrations (mean difference −5.50 ng/mL; CI 6.99 to −4.01, P < 0.001, I² = 87%) and higher odds of vitamin D deficiency (OR 3.71; CI 1.90–7.24, P < 0.001, I² = 80%).

Conclusion

This review underscores the potential of vitamin D in mitigating fibroid development and growth. While promising, further research is warranted to optimise dosage and treatment duration, potentially offering a non-invasive solution for at-risk patients. Continued exploration of vitamin D's role in fibroid treatment is encouraged.

目的：本研究旨在整合有关维生素 D 与子宫肌瘤的存在和生长之间关系的现有文献。数据来源：使用相关关键词对 MEDLINE、Embase、CINAHL、Web of Science、ClinicalTrials.gov 和灰色文献等数据库进行了全面检索，检索期从开始到 2023 年 2 月。研究筛选：从根据标题和摘要筛选出的 9931 项研究中，纳入了那些评估血清维生素 D 水平或维生素 D 治疗效果、使用超声波诊断、至少有 25 名绝经前参与者参与的研究。数据提取与综合：采用预先定义的表格提取数据。方法学质量通过纽卡斯尔-渥太华量表和偏倚风险-2工具进行评估。证据质量采用建议评估、制定和评价分级法进行评估。通过随机效应模型对来自 3 项随机对照试验（n = 328）和 23 项观察性研究（n = 5650）的数据进行了元分析。与对照组相比，接受口服维生素 D 补充剂的患者在 2-6 个月的时间里，子宫肌瘤大小的变化（SMD -5.7%，CI -10.63~-0.76，P = 0.02，I2 = 99%）明显不同（以直径或体积的百分比变化来衡量）。接受补充剂治疗的患者都存在维生素 D 不足的问题；治疗方案各不相同，有的每周 50 000 IU，持续 12 周；有的每周 50 000 IU，持续 8 周；有的每两周 50 000 IU，持续 10 周。子宫肌瘤患者的血清维生素 D 浓度较低（MD -5.50 ng/mL，CI 6.99 至 -4.01，P < 0.001，I2 = 87%），维生素 D 缺乏的几率较高（OR 3.71，CI 1.90 至 7.24，P < 0.001，I2 = 80%）。尽管前景广阔，但仍需进一步研究以优化剂量和治疗时间，从而为高危患者提供一种非侵入性的解决方案。目的：本研究旨在整合有关维生素 D 与子宫肌瘤的存在和生长之间关系的现有文献。资料来源：使用相关关键词对 MEDLINE、Embase、CINAHL、Web of Science 和 ClinicalTrials.gov 数据库和文献进行了全面检索，检索时间从开始到 2023 年 2 月。还联系了作者以获取未发表的数据。研究筛选：在根据标题和摘要筛选出的 9931 项研究中，仅纳入了评估血清维生素 D 水平或维生素 D 治疗效果、使用超声波进行诊断并纳入至少 25 名非绝经期女性的研究。病例研究、病例系列研究和综述未被纳入。数据提取与分析：采用预定义表格提取数据。方法学质量采用纽卡斯尔-渥太华量表和 RoB-2 偏倚风险评估工具进行评估。数据质量采用 GRADE（建议、评估、开发和评价分级）方法进行评估。采用随机效应模型对 3 项随机临床试验（n = 328）和 23 项观察性研究（n = 5650）的数据进行了元分析。接受口服维生素 D 补充剂的患者子宫肌瘤大小的变化明显不同（标准化平均值的差异：-5.7%；CI：-10.63 至 -0.76；P = 0.02；I2 = 99%）。接受补充剂治疗的患者缺乏维生素D，治疗方案为每周50,000 IU，持续12周；每周50,000 IU，持续8周；或每隔一周50,000 IU，持续10周。子宫肌瘤患者的血清维生素 D 浓度较低（平均差异：-5.50 ng/mL；CI：6.99 至 -4.01；P < 0.001；I2 = 87%），维生素 D 缺乏的风险较高（OR：3.71；CI：1.90 至 7.24；P < 0.001；I2 = 80%）。虽然这些研究结果很有希望，但还需要进一步研究，以优化治疗剂量和持续时间，从而为有风险的患者提供一种非侵入性的解决方案。我们鼓励进一步研究维生素D在子宫肌瘤治疗中的作用。

{"title":"The Association of Vitamin D with Uterine Fibroids in Premenopausal Patients: A Systematic Review and Meta-Analysis","authors":"Marina Ivanova BHSc, BScN , Allison Soule BSc , Jessica Pudwell MSc, MPH , Olga Bougie MD, MPH","doi":"10.1016/j.jogc.2024.102632","DOIUrl":"10.1016/j.jogc.2024.102632","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to consolidate existing literature regarding the association between vitamin D and uterine fibroid presence and growth.</div></div><div><h3>Data sources</h3><div>A comprehensive search across databases including Medline, Embase, CINAHL, Web of Science, <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, and grey literature was conducted from inception to February 2023, using relevant keywords. Authors were contacted for unpublished data.</div></div><div><h3>Study selection</h3><div>From 9931 studies screened based on title and abstract, those evaluating serum vitamin D levels or vitamin D treatment effects, using ultrasonography for diagnosis, and involving at least 25 premenopausal participants were included. Case reports, case series, and reviews were excluded.</div></div><div><h3>Data extraction and synthesis</h3><div>Data were extracted using a predefined form. Methodological quality was assessed through the Newcastle-Ottawa Scale and the Risk of Bias-2 tools. Evidence quality was evaluated using Grading of Recommendations Assessment, Development, and Evaluation. Data from 3 randomised controlled trials (n = 328) and 23 observational studies (n = 5650) were meta-analyzed via random-effects modelling. Patients receiving oral vitamin D supplementation had a significantly different change in fibroid size (standardized mean difference −5.7%; CI −10.63 to −0.76, <em>P</em> = 0.02, I<sup>2</sup> = 99%), as measured by the percentage change in diameter or volume, compared to controls, over the span of 2–6 months. Those receiving supplementation had vitamin D insufficiency; regimens varied between 50 000 IU weekly for 12 weeks, 50 000 IU weekly for 8 weeks, and 50 000 IU biweekly for 10 weeks. Patients with fibroids exhibited lower serum vitamin D concentrations (mean difference −5.50 ng/mL; CI 6.99 to −4.01, <em>P</em> < 0.001, I<sup>2</sup> = 87%) and higher odds of vitamin D deficiency (OR 3.71; CI 1.90–7.24, <em>P</em> < 0.001, I<sup>2</sup> = 80%).</div></div><div><h3>Conclusion</h3><div>This review underscores the potential of vitamin D in mitigating fibroid development and growth. While promising, further research is warranted to optimise dosage and treatment duration, potentially offering a non-invasive solution for at-risk patients. Continued exploration of vitamin D's role in fibroid treatment is encouraged.</div></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of Maternal and Infant Outcomes in SARS-CoV-2 Infected Pregnancies and Contemporaneous General Population Pregnancies From British Columbia 不列颠哥伦比亚省 SARS-CoV-2 感染孕妇与同期普通人群孕妇的母婴结局比较

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-06 DOI: 10.1016/j.jogc.2024.102631

Winnie Fu BSc , Elisabeth McClymont PhD , Gal Av-Gay MSc , Qian Zhang MPH , Jeffrey N. Bone MSc, PhD , Chelsea Elwood MSc, MD , Ashley Roberts MEd, MD , Manish Sadarangani BM, BCh, MRCPCH, DPhil , Laura Sauvé MPH, MD , Julie van Schalkwyk MSc, MD , Deborah Money MD

引用次数: 0

Masthead Pages 刊头页面

IF 2 Q2 OBSTETRICS & GYNECOLOGY

Journal of obstetrics and gynaecology Canada

Pub Date : 2024-08-01 DOI: 10.1016/S1701-2163(24)00448-1

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Journal of obstetrics and gynaecology Canada

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀